Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Terpos, E  [Clear All Filters]
Journal Article
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Kostopoulos, I. V., Paterakis G., Pavlidis D., Kastritis E., Terpos E., Tsitsilonis O. E., et al. (2017).  Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis.. Blood Cancer J. 7(8), e597.
Anastasilakis, A. D., Polyzos S. A., Avramidis A., Papatheodorou A., & Terpos E. (2009).  Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.. Horm Metab Res. 41(7), 559-62.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Kita M., Litsas I., Avramidis A., et al. (2009).  The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.. Horm Metab Res. 41(11), 846-50.
Anastasilakis, A. D., Toulis K. A., Goulis D. G., Polyzos S. A., Delaroudis S., Giomisi A., et al. (2009).  Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.. Horm Metab Res. 41(10), 721-9.
Anagnostis, P., Karras S. N., Vakalopoulou S., & Terpos E. (2016).  Haemophilia and low bone mass. Ok, but what about fracture risk?. Haemophilia. 22(1), 11-4.
Voskaridou, E., Christoulas D., Plata E., Bratengeier C., Anastasilakis A. D., Komninaka V., et al. (2012).  High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.. Horm Metab Res. 44(12), 909-13.
Eleutherakis-Papaiakovou, E., Dimopoulos M-A., Kastritis E., Christoulas D., Roussou M., Migkou M., et al. (2017).  Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.. Bone Marrow Transplant. 52(11), 1537-1542.
Polyzos, S. A., Anastasilakis A. D., Makras P., & Terpos E. (2011).  Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.. Exp Clin Endocrinol Diabetes. 119(9), 519-24.
Anagnostis, P., Vakalopoulou S., Christoulas D., Paschou S. A., Papatheodorou A., Garipidou V., et al. (2018).  The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.. Haemophilia. 24(2), 316-322.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2013).  Serum sclerostin levels following treatment with parathyroid hormone.. J Endocrinol Invest. 36(4), 280.
Polyzos, S. A., Anastasilakis A. D., Bratengeier C., Woloszczuk W., Papatheodorou A., & Terpos E. (2012).  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.. Osteoporos Int. 23(3), 1171-6.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Litsas I., Kita M., Arsos G., et al. (2011).  Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.. Osteoporos Int. 22(1), 363-7.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.